RNS Number : 2143O MaxCyte, Inc. 30 January 2023 MaxCyte, Inc. (" MaxCyte " or the "Company") Exercise of options, PDMR dealing and Total Voting Rights ROCKVILLE, MD , January 30, 2023 - MaxCyte (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell - engineering company focused on
RNS Number : 5691L MaxCyte, Inc. 04 January 2023 MaxCyte Signs Strategic Platform License with Catamaran Bio to Support its CAR-NK Cell Therapy Programs MaxCyte's Flow Electroporation® and ExPERT™ technologies to be used to enhance Catamaran's TAILWIND® platform for novel CAR-NK cell
RNS Number : 5209I MaxCyte, Inc. 05 December 2022 MaxCyte Signs Strategic Platform License with Curamys to Enable Cell & Gene Therapies for the Treatment of Rare Intractable Diseases Curamys to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform to help advance its cell
RNS Number : 5048I MaxCyte, Inc. 02 December 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 2 December 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
RNS Number : 2271I MaxCyte, Inc. 01 December 2022 MaxCyte Appoints Patrick J. Balthrop as Non-Executive Director Rockville, MD , 1 December, 2022 : MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell - engineering focused company providing enabling platform technologies to
RNS Number : 0603G MaxCyte, Inc. 11 November 2022 TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
RNS Number : 8941F MaxCyte, Inc. 10 November 2022 MaxCyte announces filing of Form 10-Q for the quarterly period ended September 30, 2022 ROCKVILLE, MD , November 10, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform
RNS Number : 8908F MaxCyte, Inc. 10 November 2022 MaxCyte Reports Third Quarter 2022 Financial Results 22% Year-Over-Year Core Business Revenue Growth in Third Quarter 2022 Reiterates 2022 Revenue Guidance ROCKVILLE, MD , November 10, 2022 - MaxCyte, Inc.
RNS Number : 0728F MaxCyte, Inc. 02 November 2022 MaxCyte to Participate in Upcoming Investor Conferences ROCKVILLE, MD , November 2, 2022 - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery,
RNS Number : 8870E MaxCyte, Inc. 01 November 2022 MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights Gaithersburg, Maryland - 1 November 2022 : MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to
